고위험 골수형성이상증후군 치료를 위한 저용량 5-Aza-2′-Deoxycytidine, DNA 저메틸화제: 노인 환자 대상 다기관 2상 연구

Wijermans 등(수요일,)이 이 문제를 연구하였습니다.

www.synapsesocial.com/papers/69ecef1dd55980bedc8fe5c1 — DOI: https://doi.org/10.1200/jco.2000.18.5.956

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome· 1997 · 202 citations
2. 5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes.· 1993 · 92 citations
3. Developmental regulation of myeloid gene expression and demethylation during ex vivo culture of peripheral blood progenitor cells· 1996 · 30 citations
4. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup study· 1992 · 115 citations
5. Limited erythropoietic response to combined treatment with recombinant human interleukin 3 and erythropoietin in myelodysplastic syndrome· 1999 · 23 citations